Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in Advanced Esophageal Squamous Cell Carcinoma
NCT03925870Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Jun 2019
- Primary completion
- Aug 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Alphamab Oncology. Started Jun 2019; status: completed.
02
Drugs
erfonrilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03925870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925870.